Cerebras vs. SpaceX: Which 2026 IPO Is the Better AI Stock to Own for the Next 5 Years?

Cerebras’ cloud and services revenue surged 287% YoY to $127.7M in Q2, with total non-GAAP revenue up 103.3% YoY to $209.9M, and it raised full-year core revenue guidance to $880M–$890M (from $855M–$865M). The article argues Cerebras could be a better AI inference-play as Gartner forecasts $23.3B of global inference spend in 2026 (vs. $19B for training), but highlights concentration risk with three customers at ~76% of Q2 revenue and only 22% of $25.4B RPO expected to convert into revenue through June 2028. Valuation is framed as lower vs SpaceX (CBRS ~14.9x 2027E revenue vs SPCX ~17.4x), despite Cerebras’ higher execution risk.

Analysis

The market is likely to over-reward the narrative shift toward inference because it improves the addressable spend mix, but the investable edge is really about who monetizes inference with the least balance-sheet strain. That favors CBRS on a relative basis: it is more directly exposed to the workload shift and has visible top-line momentum, while SPCX is using a profitable core business to subsidize an AI push that still looks like a capital sink. The second-order read-through is that capital will probably gravitate toward “picks-and-shovels” inference capacity rather than broad AI platforms with longer payback periods.

The key risk on CBRS is that the revenue base is still too concentrated to deserve a clean premium multiple. If any of the top customers slow capacity adds, the model can re-rate fast because the market is capitalizing growth that is still thinly diversified and only partially converted from backlog. That makes the next 1-2 quarters the real catalyst window: continued guidance raises and improving gross margin conversion would validate the thesis; any pause in bookings or weaker RPO conversion would expose the stock to an abrupt de-rating.

SPCX is the opposite setup: less execution fragility, but more capital-allocation risk. The Connectivity cash engine likely prevents a liquidity story from developing, yet the AI segment’s economics need to improve meaningfully before the market pays for the growth. If AI losses keep scaling faster than revenue, investors may start treating the segment like option value rather than earnings power, compressing the multiple despite the headline growth. Over 6-18 months, the winner is likely the company that proves unit economics, not the one that can fund the biggest buildout.

Key Decisions for Investors

• Long CBRS on pullbacks over the next 1-2 weeks; use recent guidance upside as a catalyst, but size small because customer concentration can reprice the name 15-25% on a single weak update.
• Pair trade: long CBRS / short SPCX as a relative-value expression on inference monetization versus capital intensity; target the spread to work over 3-6 months if CBRS keeps raising revenue guidance and SPCX AI losses remain large.
• Set an alert on CBRS customer concentration disclosures and RPO conversion rates; if the top-3 customer share stays above ~70% into the next print, treat the name as a trade, not a core compounder.
• Avoid chasing SPCX until there is evidence the AI segment is moving toward operating leverage; if AI capex remains above revenue growth for another quarter, expect multiple compression despite the stronger balance sheet.
• Watch NVDA only as a sentiment barometer, not a direct hedge; if inference demand broadens without cannibalizing training spend, the read-through is positive for the entire AI infra complex, which would blunt any short SPCX thesis.